Could HIV treatment choice affect sleep? new study investigates
NCT ID NCT07673965
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study looks at sleep health in people with HIV who are on different antiretroviral therapies. Some participants switch from a dolutegravir-based regimen to a doravirine-based one, while others stay on dolutegravir. Sleep is measured using questionnaires, wrist-worn activity monitors, and overnight sleep studies. The goal is to see if the type of HIV medication affects sleep quality and patterns.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Doravirine (Delstrigo) and dolutegravir-based antiretroviral therapy
- What this could lead to
- If differences in sleep health are found, this could help tailor HIV treatment to improve quality of life and long-term health.
- What could go wrong
- This is a small pilot study with only 40 participants, so results may not apply broadly. Sleep changes may be subtle or absent.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV (HUMAN IMMUNODEFICIENCY VIRUS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A 45-Minute lesson could sharpen Students' minds and sleep
- Cash for care: a simple incentive to keep HIV patients on track
- Olive oil as a shield? trial tests whether a daily spoonful cuts heart risks in HIV
- Are clinics missing advanced HIV cases? a new study investigates
- Can a sleepless night rewire hunger and memory?
- Melatonin bath products: are they absorbed like pills?